OGN Company Profile and Key Details

Q: Who are the executives of OGN?

Dr. Sandra Milligan J.D., M.D.Executive Vice President and Head of R&DMr. Joseph T. Morrissey Jr.Executive Vice President and Head of Manufacturing & SupplyMr. Kirke WeaverGen. Counsel & Corporation Sec.Ms. Geralyn S. RitterExecutive Vice President and Head of External Affairs & ESGMr. Kevin AliChief Executive Officer & DirectorMr. Matthew M. WalshExecutive Vice President & Chief Financial OfficerMs. Susanne Gabriele FiedlerExecutive Vice President & Chief Commercial OfficerMs. Rachel A. StahlerExecutive Vice President & Chief Information OfficerMs. Jennifer HalchakVice President of Investor RelationsMr. Aaron FalcioneExecutive Vice President & Chief HR OfficerMr. Vittorio NisitaExecutive Vice President & Head of Global Bus. Services

NYSE : OGN

Organon & Co

$13.52

-0.015-0.11%

At Close 4:00 PM

71.98

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Organon & Co. (OGN) stock declined over -0.11%, trading at $13.52 on NYSE, down from the previous close of $13.54. The stock opened at $13.53, fluctuating between $13.52 and $13.55 in the recent session.

Stock Snapshot

13.535

Prev. Close

3.55B

Market Cap

13.52

Day Low

4.04

P/E Ratio

3.35

EPS (TTM)

2.1

Cash Flow per Share

13.53

Open

262.61M

Number of Shares

13.55

Day High

99.53%

Free Float in %

-0.27

Book Value

2.04M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 28, 2026	13.52	13.55	13.52	13.52	2.33M
Jul 27, 2026	13.52	13.54	13.51	13.54	2.65M
Jul 24, 2026	13.58	13.58	13.52	13.52	3.82M
Jul 23, 2026	13.51	13.58	13.51	13.56	6.56M
Jul 22, 2026	13.52	13.54	13.52	13.52	2.49M
Jul 21, 2026	13.53	13.53	13.51	13.51	1.38M
Jul 20, 2026	13.51	13.52	13.49	13.49	1.96M
Jul 17, 2026	13.49	13.53	13.49	13.52	1.59M
Jul 16, 2026	13.49	13.51	13.49	13.49	2.7M
Jul 15, 2026	13.50	13.51	13.49	13.49	2.34M
Jul 14, 2026	13.50	13.51	13.49	13.50	1.96M
Jul 13, 2026	13.52	13.53	13.49	13.50	1.62M
Jul 10, 2026	13.49	13.53	13.48	13.52	3.02M
Jul 09, 2026	13.50	13.51	13.49	13.49	1.07M
Jul 08, 2026	13.50	13.51	13.46	13.47	4.03M
Jul 07, 2026	13.56	13.56	13.49	13.51	2.89M
Jul 06, 2026	13.55	13.58	13.50	13.56	4.25M
Jul 02, 2026	13.57	13.59	13.53	13.55	1.5M
Jul 01, 2026	13.51	13.60	13.51	13.53	2.52M
Jun 30, 2026	13.50	13.55	13.49	13.54	1.78M

Contact Details

Jersey City, NJ 07302

United States

https://www.organon.com 551 430 6000

About Company

Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.

Stock Peers

LLY

25.078+2.09%

Eli Lilly and Company$1,222.61 JNJ

0.78+0.29%

Johnson & Johnson$266.73 ABBV

6.57+2.56%

AbbVie Inc.$263.48 AZN

2.84+1.67%

AstraZeneca PLC$172.48 NVS

3.74+2.40%

Novartis AG$159.85 MRK

1.075+0.82%

Merck & Co., Inc.$131.84 ZTS

0.63+0.82%

Zoetis Inc.$77.55 BMY

1.04+1.66%

Bristol-Myers Squibb Company$63.60 GSK

1.73+3.33%

GSK plc$53.71 NVO

1.29+2.60%

Novo Nordisk A/S$50.96

Company Overview

Organon & Co. (NYSE:OGN) closed at $13.52 USD, losing -$0.02 (-0.11%) from the previous close of $13.54. The stock is currently trading near its 52-week high $5.69 and $13.60. With a market capitalization of about $3.55 billion, Organon & Co. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.54). Key stats such as the average daily volume over the past year has been around 3.77 million shares, volume is running light vs its 52-week average. Headquartered in Jersey City, NJ, Organon & Co. operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Joseph T. Morrissey Jr., the company employs approximately 10,000 people and listed since May 14, 2021. Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies.

Technical Performance

OGN has shown mixed momentum, gaining 16.5% over the past week and 1.94% over the past quarter, though year-to-date performance is up 31.94%. Short-term trend indicators are bullishly aligned (SMA20 -7.87%, SMA50 -8.86%, SMA200 -18.1%). The stock’s 14-day RSI is 40.07 (neutral), while the ATR of 0.43 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -55.15% below its high and over 16.99% above its low. Average 10-day trading volume of 3.03 million shares is below the 3-month average of 4.19 million, indicating normal recent market interest.

Valuation Metrics

Organon & Co. trades at a P/E ratio of 14.25, slightly below the S&P 500 average, with a price-to-sales ratio of 0.58 and a price-to-book ratio of 3.9 trading at moderately above to book value. The P/FCF stands at 5.79, also above market averages.

Dividend & Fair Value

Organon & Co. last paid a dividend of 0.08 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $16.47. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Organon & Co. generated EPS of $0.72 over the past year. Five-year average earnings growth is -39.04%. Wall Street analysts project EPS growth of 2.57% annually over the next five years. The latest quarter delivered EPS of $0.71. The next quarter is forecast at $0.83. Next year's EPS is expected at $3.40. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 3 Hold ratings, 0 Sell rating and 3 Strong Sell ratings. Price targets range from $14.00 to $7.50. The high target offers 3.55% upside. The low target suggests -44.53% downside. The mean target is $10.75. This offers -20.49% upside. Organon & Co. earnings surprise history is a mixed track record. The quarter that ended April 30, 2026, missed forecasts by -14.46%. The prior quarter beat by -13.7%. Over the last six quarters, Apple has recorded several small beats. These include -2.17% in February 13, 2025.

Shareholding & Insider Activity

Organon & Co. has 259.97 million shares outstanding. The public float is 258.73 million shares, elevated short interest at 7.69% of float. This equals 15.01 million shares. The short ratio is 4.1 days. Institutional investors hold 78.25% of the float. Insiders own 0.47%. Ali Kevin holds 282.73 thousand shares, WALSH MATTHEW M has 144.48 thousand shares and COX CARRIE SMITH has 77.87 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Organon & Co generated $6.26B in revenue, or $24.44 per share. Gross margin was 59.84%, operating margin 21.06%, and net profit margin 16.33%. Returns are negative, with ROA at 8.48% and ROE at -1461.43%.
On valuation metrics, Organon & Co trades at a P/E of 14.25, P/S of 0.58 and P/B of 3.90. The current ratio is 1.97 and quick ratio is 1.42. Operationally, the company’s inventory turnover is 2.10 and cash conversion cycle is 131.28 days. Debt-to-equity is 9.49, supported by a cash flow-to-debt ratio of 0.10.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Organon & Co posted revenue of $6.26B, down slightly from $6.17B in the prior quarter. Gross profit was $3.75B (margin 59.84%). Operating income was $1.32B (margin 21.1%). Net income was$1.02B (EPS $4.01).
The company ended the quarter with $693.00M in cash and short-term investments, a total debt of $8.76B, and net debt of $8.07B. Total assets were $12.06B, with equity of - $70.00M. Financials further reflected stability, with operating cash flow of $799.00M, free cash flow of $538.00M, and capital expenditures of - $261.00M.

Price Forecast & Outlook

Our AI price prediction model suggests that Organon & Co. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.44%, with price expected at $13.58 by August 11, 2026, within a range of $13.43 to $13.73 3-Month Outlook: Projected fall of -28.77%, reaching $9.63 by October 23, 2026, with a range of $7.92 to $10.60. 1-Year Outlook: Projected gain of 104.07%, with price at $27.59 by July 28, 2027, within a range of $4.22 to $45.60.

Key Takeaways

Organon & Co. (NYSE:OGN) shares are up 31.94% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Organon & Co. trading at a premium to the broader market with a P/E of 14.25. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $24.68, suggesting 82.54% upside. Our AI forecast model points to short-term strength (0.44% over two weeks), a medium-term fall (-28.77% over three months), and a longer-term gain (104.07% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Organon & Co. (OGN) stock price?

Organon & Co. (NYSE: OGN) stock price is $13.52 in the last trading session. During the trading session, OGN stock reached the peak price of $13.55 while $13.52 was the lowest point it dropped to. The percentage change in OGN stock occurred in the recent session was -0.11% while the dollar amount for the price change in OGN stock was - $0.02.

OGN's industry and sector of operation?

The NYSE listed OGN is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Organon & Co. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of OGN?

Dr. Sandra Milligan J.D., M.D.
Executive Vice President and Head of R&D
Mr. Joseph T. Morrissey Jr.
Executive Vice President and Head of Manufacturing & Supply
Mr. Kirke Weaver
Gen. Counsel & Corporation Sec.
Ms. Geralyn S. Ritter
Executive Vice President and Head of External Affairs & ESG
Mr. Kevin Ali
Chief Executive Officer & Director
Mr. Matthew M. Walsh
Executive Vice President & Chief Financial Officer
Ms. Susanne Gabriele Fiedler
Executive Vice President & Chief Commercial Officer
Ms. Rachel A. Stahler
Executive Vice President & Chief Information Officer
Ms. Jennifer Halchak
Vice President of Investor Relations
Mr. Aaron Falcione
Executive Vice President & Chief HR Officer
Mr. Vittorio Nisita
Executive Vice President & Head of Global Bus. Services

How OGN did perform over past 52-week?

OGN's closing price is 137.61% higher than its 52-week low of $5.69 where as its distance from 52-week high of $13.60 is -0.59%.

How many employees does OGN have?

Number of OGN employees currently stands at 10,000.

Link for OGN official website?

Official Website of OGN is: https://www.organon.com

How do I contact OGN?

OGN could be contacted at phone 551 430 6000 and can also be accessed through its website. OGN operates from 30 Hudson Street, Jersey City, NJ 07302, United States.

How many shares of OGN are traded daily?

OGN stock volume for the day was 2.04M shares. The average number of OGN shares traded daily for last 3 months was 3.77M.

What is the market cap of OGN currently?

The market value of OGN currently stands at $3.55B with its latest stock price at $13.52 and 262.61M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	10000
Beta	1.54
Sales or Revenue	$6.26B
5Y Sales Change%	-0.365%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

OGN Company Profile and Key Details

Organon & Co

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways